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Introduction
One-third of all patients who develop nonsmall cell lung can-
cer (NSCLC) are diagnosed with locally advanced (stage III)
disease [1]. NSCLC patients frequently develop (symptomatic)
brain metastases (BM), and the more advanced the disease
is, the more frequent BM occur. Patients with stage-III NSCLC
have a BM incidence of approximately 30% [2].
The effectiveness of prophylactic cranial irradiation (PCI)
to reduce BM has been investigated in several randomized
controlled trials (RCTs) [3–10]. The NVALT-11/DLCRG-02 trial
[11] showed that two years after PCI, the proportion of
patients with symptomatic BM was significantly lower in the
PCI arm, compared to the observation arm (7.0% vs. 27.2%,
hazard ratio (HR) 0.23, 95% confidence interval (95% CI)
(0.09-0.56), p .001). Additional analyses to assess the impact
of PCI on symptomatic BM in predefined subgroups did not
show statistically significant differences between both arms.
Literature suggests that the BM risk increases when dis-
ease stage advances and that patients with non-squamous
histology have a higher risk of developing BM than patients
with squamous histology [12,13]. Furthermore, evidence from
the literature showed that the type of (multi)modality ther-
apy may also influence the risk of developing BM [12,14].
Therefore, to obtain maximum information from the NVALT-
11/DLCRG-02 trial on top of the stratification factors, we
aimed to identify subsets of patients that may be more likely
to benefit from PCI. Specifically, we performed additional
exploratory subgroup analyses to examine the risk of devel-
oping symptomatic BM and PCI interaction effects for age
(>61 years vs. 61 years), sex (males vs. females), disease
stage (stage IIIb vs. stage IIIa) and prior treatment (total
concurrent chemo-radiotherapy (RT) time (>64 days vs. 64
days), number of chemotherapy cycles (>3 cycles vs. 3
cycles) and thoracic RT dose (>60Gy vs. 60Gy)).
Material and methods
Study
The Dutch NVALT-11/DLCRG-02 randomized phase-III trial
has been reported previously [11]. In short, after treatment
with curative intent (mostly concurrent chemo-RT) patients
with stage-III NSCLC were stratified according to histology,
WHO performance score (0-1 vs. 2) and prior surgery and
were subsequently randomized between PCI and observa-
tion. The primary endpoint of the study was the proportion
of patients developing symptomatic BM within 24 months
from randomization, defined as a combination of key symp-
toms suggesting BM (e.g., signs of increased intracranial
pressure, headache, cognitive or affective disturbances) and
MRI or CT proving evidence of BM. Follow-up assessments
took place 4 weeks, 3, 6, 12, 24 and 36 months after comple-
tion of treatment, or earlier when symptoms of BM occurred.
Both physician and patient reported measures were included
in these assessments. Brain imaging was performed only
after patients reported symptoms suggestive of BM or at the
discretion of the treating physician.
Statistical analysis
In addition to the predefined subgroup analyses previously
published [11], post hoc subgroup analyses were performed
for subgroups based on age (>61 years vs. 61 years), sex
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(males vs. females), disease stage (stage IIIb vs. stage IIIa)
and prior treatment (total concurrent chemo-RT time (>64
days vs. 64 days), number of chemotherapy cycles (>3
cycles vs. 3 cycles) and thoracic RT dose (>60Gy vs.
60Gy)). For continuous variables, the median was calcu-
lated and used as a cut-off value.
Competing risk regression (based on Fine and Gray’s pro-
portional sub hazards model), including death of any cause
as competing risk, was used to estimate HRs, 95% CIs and
corresponding cumulative incidence plots for each subgroup.
Furthermore, an interaction test was performed to test for a
PCI treatment interaction effect across each subgroup (i.e., to
test whether the effect of PCI was significantly different
across levels of each subgroup). In order to reduce the
chance of false-positive results, all statistical comparisons
were considered statistically significant using an alpha of
0.01 (two-sided). All statistical analyses were run with
Stata/SE 14.2 software.
Results
In total, 174 patients were analyzed, with a median follow-up
of 48.5 months (95% CI 39–54 months). Patients were mostly
male (65.5%), had non-squamous histology (64.2%), no prior
surgery (89.0%) and a good performance status (0 or 1:
94.8%) (Table 1).
Regardless of treatment allocation, results of the compet-
ing risk regression analyses showed that older (>61 years)
patients had a statistically significantly lower risk of develop-
ing symptomatic BM compared to younger (61 years)
patients (HR 0.25, 95% CI 0.10–0.60) (Figure 1). No statistically
significant difference in the risk of developing symptomatic
BM was observed for the other subgroups (Table 1).
Results of the competing risk regression analyses assess-
ing the impact of PCI within each level of the subgroups
showed that the risk of developing symptomatic BM for
patients in the PCI arm was statistically significantly lower
compared to patients in the observation arm for patients
with non-squamous histology (HR 0.24, 95% CI 0.08–0.70,
p¼ .009), without prior surgery (HR 0.23, 95% CI 0.09 – 0.62,
p¼ .003,), who received less than three cycles of chemother-
apy (HR 0.16, 95% CI 0.05–0.54, p¼ .003) and were younger
than 61 years at the time of randomization (HR 0.18, 95% CI
0.06–0.53, p¼ .002) (Supplementary file Figures S1-S4).
Nevertheless, across none of the subgroups a statistically sig-
nificant treatment interaction effect was observed (Table 2).
Discussion
The primary results of the NVALT-11/DLCRG-02 study showed
that PCI significantly decreased the cumulative symptomatic
BM incidence at two years after randomization [11]. This
exploratory analysis showed that, regardless of treatment,
older patients (>61 years) had a lower risk of developing
symptomatic BM than younger patients (61 years). This
finding might be explained by the higher incidence of
adenocarcinomas in younger patients in the NVALT-11/
DLCRG-02 study (47.3% vs. 34.9%), a well-known risk factor
for BM development [12,13,15]. Additionally, in none of the
subgroups, a statistically significant treatment interaction
effect was observed for PCI compared to observation.
Table 1. Results of the competing risk regression analyses to assess the risk of symptomatic BM in several subgroups.
Subgroups N (%) Hazard ratio 95% confidence interval p-value (alpha level¼.01)
Subgroups based on stratification factors
Histology
Non-squamous 111 (64.2) Reference
Squamous 62 (35.8) 0.76 0.34–1.66 .483
Surgery
No prior surgery 154 (89.0) Reference
Prior surgery 19 (11.0) 1.21 0.45–3.29 .707
WHO performance status
0 66 (38.4) Reference
1 97 (56.4) 0.86 0.41–1.83 .702
2 9 (5.2) 2.12 0.59–7.63 .251
Other subgroups
Disease stage
Stage IIIa 93 (53.8) Reference
Stage IIIb 80 (46.2) 0.97 0.47–1.98 .934
Number of cycles of chemotherapy
3 cycles 130 (76.0) Reference
>3 cycles 41 (24.0) 0.97 0.42–2.22 .943
Thoracic RT dose
60 Gy 89 (52.4) Reference
>60 Gy 81 (47.6) 1.15 0.57–2.36 .686
Total concurrent chemo-RT time
64 days 87 (50.9) Reference
>64 days 84 (49.1) 1.43 0.70–2.94 .325
Age
61 years 91 (52.3) Reference
>61 years 83 (47.7) 0.25 0.10–0.60 .002
Sex
Males 114 (65.5) Reference
Females 60 (34.5) 1.73 0.85–3.53 .133
p-values mar ked in bold indicate numbers that are statistically significant on a 99% confidence limit.
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Previously published results from studies that investigated
the risk of symptomatic BM across subgroups are in line with
our findings. A recent update of the NRG Oncology/RTOG
0214 phase III trial [16] suggested that younger patients and
patients with non-squamous histology were more likely to
develop BM. Next to that, results of a retrospective study of
Hendriks et al. [15] also reported associations between histo-
logical characteristics and age and the risk of developing
symptomatic BM after concurrent chemo-RT for stage-
III NSCLC.
This study has a number of limitations. Our subgroup
analyses were not predefined and should thus be interpreted
as hypothesis-generating. Furthermore, the main statistical
limitation of performing exploratory subgroup analyses is
that they are often underpowered, because the sample size
of clinical trials is usually calculated to evaluate the primary
objective of the study in the intention to treat population
instead of in specific subsets of patients. Another statistical
limitation of subgroup analyses is the inflated probability of
getting a false-positive result when multiple comparisons are
done. Therefore, to reduce the probability of false-positives
in our analyses an alpha level of 0.01 was used to determine
statistical significance.
In addition to PCI, adjuvant immune therapy could
decrease the incidence of BM after chemo-RT. In the PACIFIC
trial [17], the incidence of BM was approximately 50% lower
with durvalumab compared to placebo (6% vs. 12%). There
was, however, no standardized evaluation schedule for
detecting BM in this trial. The incidence of BM in the control
arm was much lower than in other prospective studies,
including the NVALT-11/DLCRG-02 trial, in which the inci-
dence was about 30%. Also in retrospective series, including
the Dutch multi-centric series of Hendriks et al. [15], the inci-
dence of BM (18%) was lower than in prospective studies,
pointing to the importance of prospective evaluations.
Conclusion
NSCLC patients after concurrent chemo-RT with older age
had a lower risk of developing symptomatic BM compared
Figure 1. Cumulative incidence plot comparing the risk of developing symptomatic BM in patients > 61 years and patients  61 years of age.
Table 2. Results of the competing risk regression analyses to assess the















Subgroups based on stratification factors
Histology
Squamous 0.23 0.05–1.11 .068 .965
Non-squamous 0.24 0.08–0.70 .009
Surgery
Prior surgery 0.21 0.02–1.89 .166 .976
No prior surgery 0.23 0.09–0.62 .003
WHO performance status
0 0.21 0.04–0.95 .043 .626
1 0.21 0.06–0.74 .015
2 0.70 0.06–8.05 .775
Other subgroups
Disease stage
Stage IIIa 0.27 0.08–0.95 .042 .818
Stage IIIb 0.20 0.06–0.71 .013
Number of cycles of chemotherapy
3 cycles 0.16 0.05–0.54 .003 .166
>3 cycles 0.59 0.14–2.55 .477
Thoracic radiotherapy dose
60 Gy 0.15 0.04–0.66 .012 .530
>60 Gy 0.29 0.09–0.92 .035
Total concurrent chemo-radiotherapy time
64 days 0.28 0.08–1.01 .051 .742
>64 days 0.21 0.06–0.72 .013
Age
61 years 0.18 0.06–0.53 .002 .361
>61 years 0.47 0.09–2.52 .376
Sex
Males 0.20 0.06–0.72 .013 .739
Females 0.27 0.08–0.95 .042
p-values mar ked in bold indicate numbers that are statistically significant on
a 99% confidence limit.
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to younger patients. Additionally, potentially due to a lack of
power, no statistically significant interaction effect was
observed, suggesting that none of the subgroups considered
benefits more from PCI.
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